Mein Warenkorb

Biotinylated Human CCR8 Protein, His,Flag&Avitag™ (Nanodisc)

User Reviews
Product Number/Spec
Price
Menge
CC8-H82D4-20ug
$1955.00
CC8-H82D4-100ug
$5870.00
ETA of in-stock products:2 business days
Gesamtanzahl Product Amount$ 0

Product Details

  • Application

    1. Cell based assay (FACS or functional assay)
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    CC chemokine receptor 8, CDw198, ChemR1, CKRL1, CKR-L1, CKRL1, CY6, GPRCL1, GPRCY6, GPR-CY6, TER-1

  • Source

    Nanodisc Biotinylated Human CCR8 Protein, His,Flag&Avitag (CC8-H82D4) is expressed from human 293 cells (HEK293). It is a membrane protein, contains complete wild type 7-transmembrane domains (TMD) and extracellular domain (ECD).

    Predicted N-terminus: Asp 2

    Request for sequence

  • Molecular Characterization

    This protein carries a polyhistidine tag, followed by a Flag tag and an Avi tag (Avitag™) at the C-terminus. The protein has a calculated MW of 60.5 kDa.

    *The isotype control of empty/mock nanodisc (Cat. No. APO-H81Q5) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Nanodisc membrane protein is wrapped by a synthetic phospholipid bilayer membrane structure, composed of membrane scaffold proteins (MSPs) and phospholipids.

    2. Synthesis Process

      Nanodisc reconstitution is a self-assembly process that starts from purified, detergent-solubilized membrane proteins and reconstitutes them into synthetic phospholipid bilayers stabilized by MSP1D1 membrane scaffold protein. This creates a stable, detergent-free environment that preserves native conformation and biological activity, with excellent homogeneity and full compatibility with cell-based assays such as FACS and binding assays in antibody discovery and screening (ELISA),etc.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Supplied as 0.2 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • Bioactivity-ELISA

     CCR8 ELISA

    Immobilized Biotinylated Human CCR8 Protein, His,Flag&Avitag (Cat. No. CC8-H82D4) at 5 μg/mL (100 μL/well) on Recombinant Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-CCR8 Antibody, Human IgG1 with a linear range of 0.6-5 ng/mL (QC tested).

    Protocol
  •  CCR8 ELISA

    Immobilized Biotinylated Human CCR8 Protein, His,Flag&Avitag (Cat. No. CC8-H82D4) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CCR8 Antibody with a linear range of 0.2-5 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     CCR8 SPR

    Anti-CCR8 Antibody captured on Protein A Chip can bind Biotinylated Human CCR8 Protein, His,Flag&Avitag (Cat. No. CC8-H82D4) with an affinity constant of 124 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

User Reviews
Publish Comment

Background Introduction

A chemokine receptor predominantly marking tumor-infiltrating regulatory T cells (Tregs) rather than peripheral Tregs. Targeting CCR8 enables selective depletion of immunosuppressive cells within the tumor microenvironment, thereby reinvigorating anti-tumor immunity without triggering systemic autoimmunity.

Frontier Progress

 
Drug Development Progress
  • English Name:

    C-C chemokine receptor type 8

  • Category:

  • Listed Drugs Count:

    0 Details

  • Clinical Drugs Count:

    20 Details

  • Highest R&D Stage:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
  • Hintergrund
Kontaktieren Sie uns